帕西生长素(Somapacitan) - 药物靶点：GHR_在研适应症：生长激素缺乏症，侏儒症，特发性矮小症_专利_临床

概要

基本信息

药物类型

激素

别名

Albumin-binding somatropin、Growth hormone derivative、Long-acting growth hormone

+ [18]

靶点

GHR

作用机制

GHR激动剂(生长激素受体激动剂)

治疗领域

神经系统疾病内分泌与代谢疾病心血管疾病+ [4]

在研适应症

生长激素缺乏症侏儒症特发性矮小症+ [3]

非在研适应症

垂体性侏儒症肝功能衰竭

原研机构

Novo Nordisk A/S

在研机构

Novo Nordisk A/SNovo Nordisk Pharma Ltd.Novo Nordisk Pharmaceuticals Pty Ltd.

+ [2]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2020-08-28),

生长激素缺乏症

最高研发阶段(中国)申请上市

特殊审评孤儿药 (欧盟)

登录后查看首次获批时间轴

序列信息

Sequence Code 525411697

来源: *****

关联

29

项与帕西生长素相关的临床试验

NCT06109935 / Enrolling by invitationN/A

A Multi-centre, Prospective, Open Label, Single-arm, Non-interventional Post-marketing Study to Investigate the Long-term Safety and Clinical Parameters of Sogroya® Treatment in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed Under Normal Clinical Practice Conditions in Japan Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency (GHD) Where Epiphysial Discs Are Not Closed

The purpose of the study is to investigate the safety and effectiveness of Sogroya® in children with short stature due to growth hormone deficiency where epiphysial discs are not closed under real-world clinical practice in Japan. The study will last for about 1 year (at shortest) to 3 years (at longest) depending on when the participant takes part in the study. The participant will be asked to answer questionnaire(s) about how they feel about the growth hormone (GH) product treatment once during the study (at about 3 months after starting the Sogroya® treatment) and about 3 months after starting the Sogroya® treatment.

开始日期2023-10-04

申办/合作机构

Novo Nordisk A/S

CTIS2022-501055-87-01 / Not yet recruiting

A study evaluating the safety and efficacy of once-weekly dosing of somapacitan in a basket study design in paediatric participants with short stature either born small of gestational age or with Turner syndrome, Noonan syndrome or idiopathic short stature - NN8640-4469

开始日期2023-06-19

申办/合作机构

Novo Nordisk A/S

CTR20230084 / Active, not recruiting临床3期

一项在篮式研究设计中比较 somapacitan 每周一次给药与Norditropin® 每日给药在出生时小于胎龄儿或患有特纳综合征、努南综合征或特发性身材矮小的矮身材儿童中的有效性和安全性，以及评估 somapacitan 长期安全性的研究

本研究的目的是了解与Norditropin®相比，Somapacitan用于治疗出生时体型偏小且持续偏小，或患有特纳综合征、努南综合征，或特发性身材矮小的儿童的疗效如何。

开始日期2023-02-10

申办/合作机构

诺和诺德（中国）制药有限公司

[+1]

100 项与帕西生长素相关的临床结果

登录后查看更多信息

100 项与帕西生长素相关的转化医学

登录后查看更多信息

100 项与帕西生长素相关的专利（医药）

登录后查看更多信息

9,027

项与帕西生长素相关的文献（医药）

2024-12-31·GYNECOLOGICAL ENDOCRINOLOGY

Effects of growth hormone therapy on the onset and progression of pubertal development in girls with idiopathic short stature

Review

作者: Zhu, Feng ; Zhu, Jieqian ; Zhang, Yu ; Huang, Lina ; Xu, Qi ; Huang, Lingxiao

OBJECTIVE:

The aim of this study was to explore the impact of growth hormone (GH) therapy on the onset and progression of puberty in girls with idiopathic short stature.

METHODS:

This study included 541 girls aged between 4.5 and 10.6 years who were receiving GH treatment, monitored over a 22-year follow-up period. Of these, 126 girls have been followed up to the onset of menarche. The participants were divided into two groups: a ISS control group (n = 66) and a group receiving daily GH treatment at a dose of 0.15 iu/kg (n = 60). We assessed the pubertal development and GH usage of these girls every three months.

RESULTS:

(1) There was no significant difference in the onset of puberty between the growth hormone (GH) treatment group and the control group; however, the average duration of puberty was longer in the treatment group compared to the control group. (2) During puberty, there were no significant differences in height growth between the treated and untreated groups. (3) The duration of GH treatment showed a significant negative correlation with the age at onset of gonadal development and the age at menarche in females within the treatment group.

CONCLUSION:

GH treatment does not seem to accelerate the onset of puberty but may extend its duration, without significantly impacting height growth during puberty. Additionally, longer GH treatment duration is linked to earlier gonadal development and menarche in females.

2024-11-01·EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Growth hormone augmentation in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials

Review

作者: Hussain, Sophia ; Duong, Nikki ; Kotak, Anaya ; Qureshi, Raabia ; Alba, Laura ; Mohamed, Islam ; Gautam, Misha ; Jaber, Fouad ; Abosheaishaa, Hazem ; Dahiya, Dushyant Singh ; Baugh, Macy ; Kumar, Kopal

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by hepatic steatosis and metabolic dysregulation. Growth hormone (GH) augmentation has emerged as a potential therapeutic intervention for treating MASLD. This systematic review and meta-analysis aimed to evaluate the impact of GH augmentation on different parameters of MASLD. A systematic literature search identified randomized controlled trials investigating GH augmentation in MASLD patients. Search results were screened via Covidence and the Risk of Bias 2 tool was used to assess bias in randomized controlled trials. Statistical analysis utilized RevMan v5.3. We combined dichotomous outcomes employing odds ratios and continuous outcomes utilizing mean difference (MD), each with a 95% confidence interval (CI). Statistical significance was indicated by a P-value less than 0.05. Heterogeneity was evaluated using I2 tests. Our results showed that GH augmentation resulted in a significant reduction in both relative (MD: −46.26; 95% CI: −71.52, −21.00; P = 0.0003) and absolute (MD: −5.15; 95% CI: −7.93, −2.37; P = 0.0003) hepatic fat fraction. GH augmentation significantly reduced alanine aminotransferase (MD: −5.97; 95% CI: −10.31, −1.62; P = 0.007) and gamma-glutamyl transferase (MD: −16.18; 95% CI: −30.76, −1.59; P = 0.03) levels. No significant changes were observed in hemoglobin A1c, C-reactive protein, fasting serum glucose, BMI, triglycerides, and low-density lipoprotein cholesterol levels. Our meta-analysis highlights GH augmentation as a promising therapy for reducing liver steatosis and improving liver enzyme levels in MASLD patients. Further large-scale trials are warranted to examine the long-term effects, safety profiles, and potential impact on various measures.

2024-11-01·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY

Direct actions of growth hormone in rainbow trout, Oncorhynchus mykiss, skeletal muscle cells in vitro

Article

作者: Biga, Peggy R ; Turkmen, Serhat ; Reid, Ross M ; Cleveland, Beth M

The growth hormone (GH)-insulin-like growth factor-1 (IGF-1) system regulates skeletal muscle growth and function. GH has a major function of targeting the liver to regulate IGF-1 production and release, and IGF-1 mediates the primary anabolic action of GH on growth. However, skeletal muscle is a target tissue of GH as evidenced by dynamic GH receptor expression, but it is unclear if GH elicits any direct actions on extrahepatic tissues as it is difficult to distinguish the effects of IGF-1 from GH. Fish growth regulation is complex compared to mammals, as genome duplication events have resulted in multiple isoforms of GHs, GHRs, IGFs, and IGFRs expressed in most fish tissues. This study investigated the potential for GH direct actions on fish skeletal muscle using an in vitro system, where rainbow trout myogenic precursor cells (MPCs) were cultured in normal and serum-deprived media, to mimic in vivo fasting conditions. Fasting reduces IGF-1 signaling in the muscle, which is critical for disentangling the roles of GH from IGF-1. The direct effects of GH were analyzed by measuring changes in myogenic proliferation and differentiation genes, as well as genes regulating muscle growth and proteolysis. This study provides the first in-depth analysis of the direct actions of GH on serum-deprived fish muscle cells in vitro. Data suggest that GH induces the expression of markers for proliferation and muscle growth in the presence of serum, but all observed GH action was blocked in serum-deprived conditions. Additionally, serum deprivation alone reduced the expression of several proliferation and differentiation markers, while increasing growth and proteolysis markers. Results also demonstrate dynamic gene expression response in the presence of GH and a JAK inhibitor in serum-provided but not serum-deprived conditions. These data provide a better understanding of GH signaling in relation to serum in trout muscle cells in vitro.

111

项与帕西生长素相关的新闻（医药）

2024-09-30

·GlobeNewswire-Health Care

Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food & Drug Administration (FDA) for TransCon hGH (marketed as SKYTROFA® (lonapegsomatropin-tcgd) in the U.S. for pediatric growth hormone deficiency) for the treatment of adults with growth hormone deficiency (GHD). “The sBLA submission for TransCon hGH for adult GHD supports our strategy to develop SKYTROFA into a blockbuster product through label expansion and build upon our value leadership position in the U.S. growth hormone market,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer. “Growth hormone plays a vital role in human health at all ages, and, with research showing that the majority of adults living with growth hormone deficiency are not currently treated for this condition, we believe once weekly TransCon hGH could provide a new potential treatment option to address this unmet medical need.” The submission is based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily hGH in adults with GHD. The trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake with approximately equivalent hGH mg/week for TransCon hGH and daily hGH. TransCon hGH demonstrated superiority on its primary efficacy and key secondary efficacy endpoints at Week 38, with TransCon hGH-treated patients showing a statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo. TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH. About Ascendis Pharma A/SAscendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more. About Adult Growth Hormone DeficiencyGrowth hormone plays an essential role in the health of children and adults, promoting normal growth in children and maintenance of normal body composition and cardiometabolic health throughout adulthood. In adults, growth hormone boosts protein production, promotes fat utilization, enhances muscle mass, and helps regulate blood sugar levels. Adult GHD is a condition in which an individual’s body does not produce enough growth hormone. Symptoms and morbidity can include central obesity, metabolic syndrome, decreased bone density, alterations in lipid profile and markers of cardiovascular risk, fatigue, general weakness, lack of muscle tone, and psychological symptoms such as cognitive impairment, social isolation, lack of motivation, and depression.1 Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ intent to develop SKYTROFA into a blockbuster product through label expansion and build upon its value leadership position in the U.S. growth hormone market, (ii) TransCon hGH’s potential to provide a new treatment option to address the unmet medical needs of adults living with growth hormone deficiency, (iii) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (iv) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ prospectus supplement filed on September 20, 2024 and Ascendis’ current and future reports filed with, or submitted to, the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 20-F filed with the SEC on February 7, 2024. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, and SKYTROFA® are trademarks owned by the Ascendis Pharma group. © September 2024 Ascendis Pharma A/S. Investor Contacts:Media Contact:Tim LeeMelinda BakerAscendis PharmaAscendis Pharma+1 (650) 374-6343+1 (650) 709-8875tle@ascendispharma.commedia@ascendispharma.comir@ascendispharma.com Patti Bank ICR Westwicke +1 (415) 513-1284 patti.bank@westwicke.com 1.Hoffman AR, Mathison T, Andrews D, Murray K, Kelepouris N, Fleseriu M. Adult Growth Hormone Deficiency: Diagnostic and Treatment Journeys From the Patients' Perspective. J Endocr Soc. 2022;6(7):bvac077. Published 2022 May 12. doi:10.1210/jendso/bvac077

临床3期临床结果

2024-09-26

·GlobeNewswire-Health Care

Kaida BioPharma to Present at BioSparkVA Pitch Event

FORT LAUDERDALE, FL, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma company dedicated to advancing ovarian cancer treatment through innovative drug development, today announced that Craig Pierson, Chairman and Founder of Kaida BioPharma, will present at BioSparkVA's BioSpark Pitch Event, hosted by CVILLE Biohub and Cooley, taking place today, September 26, 2024 in Charlottesville, Virginia. Kaida is advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women. The Company’s lead program, KAD101 is a novel biologic that blocks the prolactin receptor to prevent cancer cell growth signals and incite autophagy initially targeting ovarian cancer. KAD101 has demonstrated encouraging results in a human clinical study with all patients showing tumor reduction with a clean safety profile as a daily injectable. The Company continues to progress the development of KAD101 toward the launch of its Phase 1 study, expected to commence in 2025. Additionally, the Company is advancing KAD102, an enhanced pure antagonist of KAD101, for the treatment of uterine cancer. For more information about the BioSpark Pitch Event, visit the event website. About Kaida BioPharma Kaida BioPharma was founded on the research principles and clinical evidence of KAD101 (Originally G129R), a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit kaida-biopharma.com. Investor ContactJenene ThomasChief Executive OfficerJTC Team, LLCT: 908.824.0775E: kaida@jtcir.com

临床1期

2024-09-25

·GlobeNewswire-Health Care

Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand. Abstract Presentation: Thursday, October 3rd – Oral Session: Growth & Puberty – 2:30PM Local Time Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to the Oral Growth Hormone (GH) Secretagogue, LUM-201, in Paediatric Growth Hormone Deficiency (PGHD) in the OraGrowtH210 Trial (Paul Hofman, MD, et al) About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Investor & Media Contact: Lisa MillerLumos Pharma Investor Relations512-792-5454ir@lumos-pharma.com Source: Lumos Pharma, Inc.

临床2期孤儿药

100 项与帕西生长素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11194	帕西生长素	H01AC01	DB15093

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
生长激素缺乏症	美国	Novo Nordisk, Inc.	2020-08-28

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
侏儒症	临床3期	美国	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	中国	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	日本	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	奥地利	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	比利时	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	巴西	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	保加利亚	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	加拿大	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	克罗地亚	Novo Nordisk A/S	2022-08-10
侏儒症	临床3期	芬兰	Novo Nordisk A/S	2022-08-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03878446 (REAL5, Pubmed \| J Clin Endocrinol Metab)	临床2期	小于胎龄儿 insulin-like growth factor I (IGF-I)	62	Somapacitan 0.16 mg/kg/week	蓋衊艱網窪網鏇鬱築顧(願積鏇廠選淵顧顧齋鹹) = 蓋艱選壓鬱築鬱鹽顧製淵鹹膚鹽襯衊醖衊選獵 (觸艱夢鑰齋簾窪膚膚範 )	积极	2024-09-13
				Somapacitan 0.20 mg/kg/week	蓋衊艱網窪網鏇鬱築顧(願積鏇廠選淵顧顧齋鹹) = 蓋鏇廠願範製觸淵鬱蓋淵鹹膚鹽襯衊醖衊選獵 (觸艱夢鑰齋簾窪膚膚範 )
NCT03811535 (REAL4, ESPE2023)	临床3期	生长激素缺乏症 IGF-I SDS	132	Once-weekly somapacitan 0.16 mg/kg/week	夢鏇襯艱廠憲襯願餘衊(願鬱膚鬱築鬱選艱築糧) = A low number of patients reported injection-site reactions in the second year, with no injection-site pain reported 觸襯網衊餘範鹽選鏇繭 (蓋製襯積糧鏇製範壓膚 ) 更多	积极	2023-09-21
				Daily GH (0.034 mg/kg/day Norditropin)
NCT03811535 (Pubmed)	临床3期	生长激素缺乏症	200	Somapacitan	蓋襯醖糧糧壓願選齋遞(繭夢艱夢壓鹹網蓋遞艱) = 廠鏇鏇遞襯顧願鏇膚憲艱壓願齋簾窪窪壓願餘 (選餘繭製繭夢築鏇繭衊 )	-	2023-07-05
				Daily GH	蓋襯醖糧糧壓願選齋遞(繭夢艱夢壓鹹網蓋遞艱) = 獵鏇膚構醖蓋簾醖積壓艱壓願齋簾窪窪壓願餘 (選餘繭製繭夢築鏇繭衊 )
NCT03878446 (ESPE2022)	临床2期	小于胎龄儿	62	Somapacitan 0.16 mg/kg/week	(鏇繭鏇膚選獵膚觸淵構) = detected in one child in the GH 0.067 mg/kg/day arm; none were detected in other treatment arms 餘蓋鏇構鬱齋願網廠襯 (廠鑰積憲遞構範獵網衊 ) 更多	-	2022-09-15
				Somapacitan 0.20 mg/kg/week
NCT03811535 (REAL4, Pubmed) 人工标引	临床3期	生长激素缺乏症	200	somapacitan	獵觸糧觸鏇廠糧築齋範(範觸窪獵廠範憲艱壓壓) = 窪顧簾鬱糧鬱鹹鹹積構艱積餘顧構構願齋鑰遞 (製衊窪鏇憲夢觸餘鑰繭 ) 更多	相似	2022-09-05
				Recombinant Human Growth Hormone	獵觸糧觸鏇廠糧築齋範(範觸窪獵廠範憲艱壓壓) = 衊醖襯艱獵築築糧鑰艱艱積餘顧構構願齋鑰遞 (製衊窪鏇憲夢觸餘鑰繭 ) 更多
NCT02962440 (Pubmed \| Eur J Pharm Sci)	临床1期	垂体性侏儒症 \| 生长激素缺乏症	7	Somapacitan 6 mg	鹽齋餘齋築窪範製鏇夢(構遞鹽衊積鹽襯積醖築) = Two subjects had six adverse events (AEs); all were mild in severity and unlikely to be related to trial product 築觸窪構膚積遞網衊獵 (齋夢獵鹹蓋鏇觸鹹鑰鹽 )	-	2021-09-30
NCT03075644 (Pubmed \| Clin Endocrinol (Oxf)) 人工标引	临床3期	生长激素缺乏症	62	Somapacitan	觸繭醖鹽膚壓鹽鏇齋繭(鏇繭願艱製構窪鑰憲鏇) = 衊簾網膚築積顧製鬱顧鹽遞築願齋醖構餘淵範 (憲衊築構範廠衊網糧鑰 ) 更多	优效	2020-11-01
				GH	觸繭醖鹽膚壓鹽鏇齋繭(鏇繭願艱製構窪鑰憲鏇) = 淵築鏇繭齋遞網齋積蓋鹽遞築願齋醖構餘淵範 (憲衊築構範廠衊網糧鑰 ) 更多
NCT03075644 (CTgov)	临床3期	生长激素缺乏症	62	somapacitan	積顧顧糧鹽鹹鑰遞選選(窪壓鏇夢鏇餘艱顧蓋願) = 齋顧襯鏇衊膚觸窪繭觸構艱廠膚範蓋襯憲餘餘 (簾積齋範構築獵夢積醖, 淵願淵鏇選網觸願鑰醖 ~ 鑰網糧淵範觸製網窪鬱) 更多	-	2020-10-06
NCT02382939 (REAL 2, CTgov)	临床3期	生长激素缺乏症	92	somapacitan	憲衊鹹鑰壓遞積糧願獵(觸窪鹹艱簾憲餘夢構鹹) = 鏇鏇顧糧鹽鹽網壓廠觸鏇襯蓋鑰廠夢夢餘願鹹 (簾繭築繭鬱製膚襯窪淵, 繭憲鬱膚繭鑰憲製鬱鹽 ~ 積夢範鹹窪遞繭糧獵簾) 更多	-	2020-06-16
NCT02616562 (REAL 3, Pubmed \| J Clin Endocrinol Metab)	临床2期	垂体性侏儒症	59	Somapacitan 0.04mg/kg/week	網築膚壓襯遞願襯範鏇(窪齋網願窪繭構齋觸憲) = 窪鑰範範範糧簾鬱願獵餘膚糧願齋簾鏇製衊餘 (餘衊衊顧艱獵選鏇醖遞 )	-	2020-04-01
				Somapacitan 0.08mg/kg/week	網築膚壓襯遞願襯範鏇(窪齋網願窪繭構齋觸憲) = 窪衊範餘膚廠繭壓鬱糧餘膚糧願齋簾鏇製衊餘 (餘衊衊顧艱獵選鏇醖遞 )